Brief: Vivesto Announces Positive Preclinical Data For Cantrixil In Hematological Cancer
01/04/2025 07:05
April 1 (Reuters) - Vivesto AB VIVE.ST: ANNOUNCES POSITIVE PRECLINICAL DATA FOR CANTRIXIL IN HEMATOLOGICAL CANCER CANTRIXIL TREATMENT WELL TOLERATED AND SAFE Source text: ID:nMFNbn4Kht Further company coverage: VIVE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))